
Quarterly report 2025-Q3
added 11-13-2025
VolitionRx Limited Net Debt 2011-2026 | VNRX
Net Debt can be roughly defined as financial liabilities that an entity classifies in the financing section together with the resources available to service those financial liabilities[1]
Net debt is the obligations that remain after deducting all assets and other liabilities from a company or individual. It represents the sum of debts that an organization or person must repay to their creditors or other parties.
Net debt can include various types of obligations such as loans, borrowings, lease liabilities, or credit card payments. It is important to note that net debt does not include current expenses or obligations such as payroll expenses or current bills.
Assessing net debt is an important financial indicator for evaluating the financial position of a company or individual. If net debt significantly exceeds assets, it may indicate financial difficulties and insolvency. In such cases, the company or individual may face difficulties in meeting their obligations and managing their finances.
Net debt can also be used to compare the financial stability of different companies. The lower the net debt relative to assets, the more stable and financially sound they are considered.
Overall, understanding net debt helps evaluate the financial soundness and ability of a company to meet their obligations. It is an important indicator that assists in making decisions about lending, investments, and financial management.
Annual Net Debt VolitionRx Limited
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 910 K | -16.9 M | -7.84 M | -18.1 M | 4.29 M | -13.2 M | -10 M | -7.3 M | -20.1 M | -5.25 M | -1.79 M | -460 K | 313 K | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 4.29 M | -20.1 M | -7.35 M |
References
- Pizzo, M., Moscariello, N., & Vinciguerra, R. (2015). Market Incentives and Regulators' Activity Shaping Financial Information: An Analysis of the Net Debt Disclosure in Italy. International Journal of Business and Management, 10(1), 1.
Net Debt of other stocks in the Diagnostics research industry
| Issuer | Net Debt | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Centogene N.V.
CNTG
|
1.18 M | - | -6.23 % | $ 30.6 M | ||
|
Akumin
AKU
|
1.21 B | - | -17.87 % | $ 25.9 M | ||
|
Brainsway Ltd.
BWAY
|
-6.88 M | $ 24.58 | 1.91 % | $ 99.4 M | ||
|
BioNano Genomics
BNGO
|
-2.64 M | $ 1.12 | -0.88 % | $ 1.42 M | ||
|
Burning Rock Biotech Limited
BNR
|
-76 M | $ 28.4 | -1.41 % | $ 306 M | ||
|
Aspira Women's Health
AWH
|
-10.9 M | - | -6.19 % | $ 10.5 M | ||
|
Accelerate Diagnostics
AXDX
|
-33.3 M | - | -61.36 % | $ 2.46 M | ||
|
Celcuity
CELC
|
82.8 M | $ 106.01 | 0.82 % | $ 4.18 B | ||
|
Biocept
BIOC
|
-11.2 M | - | -13.05 % | $ 7.29 M | ||
|
Oxford Immunotec Global PLC
OXFD
|
-173 M | - | - | $ 562 M | ||
|
Check-Cap Ltd.
CHEK
|
-11.6 M | - | - | $ 9.42 M | ||
|
Chembio Diagnostics
CEMI
|
-17.2 M | - | 0.22 % | $ 16.8 M | ||
|
DarioHealth Corp.
DRIO
|
-12.1 M | $ 11.26 | - | $ 319 M | ||
|
Enzo Biochem
ENZ
|
-51.3 M | - | -8.98 % | $ 14.8 K | ||
|
Co-Diagnostics
CODX
|
-11.9 M | - | - | $ 79.8 M | ||
|
Global Cord Blood Corporation
CO
|
-6.07 B | - | - | $ 399 M | ||
|
Fluidigm Corporation
FLDM
|
-5.38 M | - | 1.08 % | $ 308 M | ||
|
Fulgent Genetics
FLGT
|
-53.3 M | $ 23.02 | 0.04 % | $ 696 M | ||
|
Genetic Technologies Limited
GENE
|
-11.1 M | - | - | $ 7.1 B | ||
|
Genetron Holdings Limited
GTH
|
-1.35 B | - | 0.12 % | $ 80.1 M | ||
|
Quest Diagnostics Incorporated
DGX
|
5.24 B | $ 209.34 | 0.95 % | $ 23.2 B | ||
|
Castle Biosciences
CSTL
|
-108 M | $ 30.02 | 3.73 % | $ 834 M | ||
|
PRA Health Sciences, Inc.
PRAH
|
769 M | - | - | $ 10.7 B | ||
|
CareDx, Inc
CDNA
|
-48 M | $ 19.18 | 2.08 % | $ 1.03 B | ||
|
Danaher Corporation
DHR
|
14 B | $ 209.79 | -0.58 % | $ 153 B | ||
|
DermTech
DMTK
|
-33.6 M | - | -11.32 % | $ 2.94 M | ||
|
DexCom
DXCM
|
-842 M | $ 72.99 | -0.38 % | $ 28.5 B | ||
|
Interpace Biosciences
IDXG
|
105 K | $ 1.74 | -5.95 % | $ 7.63 M | ||
|
Exact Sciences Corporation
EXAS
|
-916 M | $ 103.46 | 0.07 % | $ 19.5 B | ||
|
Guardant Health
GH
|
1.15 B | $ 96.45 | 2.15 % | $ 12.1 B | ||
|
QIAGEN N.V.
QGEN
|
1.31 B | - | - | $ 10.6 B | ||
|
Laboratory Corporation of America Holdings
LH
|
4.74 B | $ 287.1 | 0.62 % | $ 24.1 B | ||
|
Charles River Laboratories International
CRL
|
1.98 B | $ 166.77 | 1.98 % | $ 8.27 B | ||
|
Heska Corporation
HSKA
|
-153 M | - | - | $ 1.31 B | ||
|
HTG Molecular Diagnostics
HTGM
|
-11.2 M | - | -20.0 % | $ 1.06 M | ||
|
ICON Public Limited Company
ICLR
|
4.63 B | $ 104.81 | 0.14 % | $ 8.65 B | ||
|
ENDRA Life Sciences
NDRA
|
-4.37 M | $ 3.77 | 0.53 % | $ 2.02 M | ||
|
IDEXX Laboratories
IDXX
|
222 M | $ 648.66 | 4.1 % | $ 52.2 B | ||
|
Illumina
ILMN
|
-494 M | $ 123.46 | 2.42 % | $ 19.6 B | ||
|
IQVIA Holdings
IQV
|
12 B | $ 164.94 | 1.75 % | $ 28.4 B | ||
|
Motus GI Holdings
MOTS
|
-3.55 M | - | -34.28 % | $ 263 K | ||
|
Koninklijke Philips N.V.
PHG
|
2.48 B | $ 31.48 | 0.82 % | $ 20 B | ||
|
Mettler-Toledo International
MTD
|
2.06 B | $ 1 382.99 | -0.81 % | $ 28.5 B | ||
|
Biodesix
BDSX
|
14.5 M | $ 13.28 | 3.99 % | $ 1.72 B | ||
|
Quidel Corporation
QDEL
|
-377 M | $ 22.06 | 4.11 % | $ 929 M | ||
|
Natera
NTRA
|
-177 M | $ 209.72 | 0.18 % | $ 20.6 B | ||
|
Lantheus Holdings
LNTH
|
-346 M | $ 73.43 | 0.01 % | $ 5.08 B | ||
|
Biomerica
BMRA
|
-1.94 M | $ 2.11 | 0.49 % | $ 4.85 M | ||
|
Bioventus
BVS
|
334 M | $ 8.71 | 0.58 % | $ 546 M | ||
|
Medpace Holdings
MEDP
|
-360 M | $ 442.92 | -0.46 % | $ 12.8 B |